This is a competitive renewal for R01 AG 029672, which applied modern psychometric methods to neuropsychological data collected by the Alzheimer's Disease Neuroimaging Initiative (ADNI). This competitive renewal proposes to analyze data from ADNI and from the Australian Imaging, Biomarkers, and Lifestyles of Ageing (AIBL) study using state-of-the-art psychometric approaches to address substantively important questions in Alzheimer's disease (AD) research. This project in many ways serves as a bridge between fields that do not often talk with each other: modern psychometrics and cognitive neuroscience applied to neurodegenerative conditions. The investigators propose to tackle two important problems in AD research: improving the ability to detect preclinical disease at the earliest stages (Aim 1) and understanding the clinical relevance of heterogeneity in the presentation of AD (Aim 2). Advances in modern psychometrics have the potential to optimize understanding of these critical questions by translating clinical insights into quantitative analytic approaches. The investigators have a tradition of disseminating their tools to the broader research community and propose to continue this tradition with a dissemination aim (Aim 3). Support for the next cycle of funding for this project will ensure continued scientific leadership bridging modern psychometrics and cognitive neuroscience.
Alzheimer's disease is an important threat to the quality of life of older adults and their families and the U.S. and world economies. This project proposes to analyze extensive cognitive, neuroimaging, and fluid biomarker data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and from the Australian Imaging Biomarkers and Lifestyles of Ageing (AIBL) studies to optimize psychometric strategies to address substantively important questions on Alzheimer's disease and the aging brain. These investigations are concordant with the mission of the National Institute on Aging.
Showing the most recent 10 out of 44 publications
